WO2008102452A1 - Hgf製剤 - Google Patents
Hgf製剤 Download PDFInfo
- Publication number
- WO2008102452A1 WO2008102452A1 PCT/JP2007/053316 JP2007053316W WO2008102452A1 WO 2008102452 A1 WO2008102452 A1 WO 2008102452A1 JP 2007053316 W JP2007053316 W JP 2007053316W WO 2008102452 A1 WO2008102452 A1 WO 2008102452A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hgf
- hgf preparation
- preparations
- preparation
- characteristic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本発明はHGFおよび精製白糖を含有するHGF製剤である。本HGF製剤は長期間の保存でも安定であるという特長を有する。
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2007/053316 WO2008102452A1 (ja) | 2007-02-22 | 2007-02-22 | Hgf製剤 |
JP2009500236A JP5265514B2 (ja) | 2007-02-22 | 2008-02-21 | Hgf製剤 |
PCT/JP2008/052979 WO2008102849A1 (ja) | 2007-02-22 | 2008-02-21 | Hgf製剤 |
KR1020097016540A KR101492511B1 (ko) | 2007-02-22 | 2008-02-21 | Hgf 제제 |
CN2013102442581A CN103356995A (zh) | 2007-02-22 | 2008-02-21 | Hgf制剂 |
CA2675622A CA2675622C (en) | 2007-02-22 | 2008-02-21 | Hgf preparation |
EP08711762.8A EP2119449B1 (en) | 2007-02-22 | 2008-02-21 | Hgf preparation |
CNA2008800016430A CN101578106A (zh) | 2007-02-22 | 2008-02-21 | Hgf制剂 |
US12/432,651 US8461112B2 (en) | 2007-02-22 | 2009-04-29 | HGF preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2007/053316 WO2008102452A1 (ja) | 2007-02-22 | 2007-02-22 | Hgf製剤 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/053316 Continuation-In-Part WO2008102452A1 (ja) | 2007-02-22 | 2007-02-22 | Hgf製剤 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/053316 Continuation-In-Part WO2008102452A1 (ja) | 2007-02-22 | 2007-02-22 | Hgf製剤 |
PCT/JP2008/052979 Continuation-In-Part WO2008102849A1 (ja) | 2007-02-22 | 2008-02-21 | Hgf製剤 |
PCT/JP2008/052979 Continuation WO2008102849A1 (ja) | 2007-02-22 | 2008-02-21 | Hgf製剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008102452A1 true WO2008102452A1 (ja) | 2008-08-28 |
Family
ID=39709738
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/053316 WO2008102452A1 (ja) | 2007-02-22 | 2007-02-22 | Hgf製剤 |
PCT/JP2008/052979 WO2008102849A1 (ja) | 2007-02-22 | 2008-02-21 | Hgf製剤 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/052979 WO2008102849A1 (ja) | 2007-02-22 | 2008-02-21 | Hgf製剤 |
Country Status (6)
Country | Link |
---|---|
US (1) | US8461112B2 (ja) |
EP (1) | EP2119449B1 (ja) |
KR (1) | KR101492511B1 (ja) |
CN (2) | CN101578106A (ja) |
CA (1) | CA2675622C (ja) |
WO (2) | WO2008102452A1 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2010321531C1 (en) * | 2009-11-23 | 2020-10-01 | Cubist Pharmaceuticals Llc | Lipopeptide compositions and related methods |
JP6426410B2 (ja) * | 2013-09-11 | 2018-11-21 | 第一三共株式会社 | 室温保存用凍結乾燥製剤 |
SG11201608583YA (en) | 2014-04-28 | 2016-11-29 | Eisai R&D Man Co Ltd | Lyophilized formulation of hgf |
DK3192524T3 (da) * | 2014-09-10 | 2022-02-14 | Kringle Pharma Inc | Hgf præparat egnet til behandling af neurologiske lidelser |
KR102275262B1 (ko) | 2016-03-17 | 2021-07-12 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 활성 간세포 성장 인자(hgf)를 생성하는 방법 |
BR112022015170A2 (pt) | 2020-03-12 | 2022-10-11 | Baxter Int | Formulações de daptomicina contendo uma combinação de sorbitol e manitol |
JPWO2021215375A1 (ja) | 2020-04-20 | 2021-10-28 | ||
BR112023022474A2 (pt) | 2021-05-14 | 2024-01-09 | Claris Biotherapeutics Inc | Composições de fator de crescimento para o tratamento de doença ocular |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6289628A (ja) * | 1985-09-11 | 1987-04-24 | Green Cross Corp:The | 人フイブリノゲン製剤の加熱処理法 |
JPH0925241A (ja) * | 1995-07-11 | 1997-01-28 | Snow Brand Milk Prod Co Ltd | Hgf凍結乾燥製剤 |
CN1579544A (zh) * | 2003-08-09 | 2005-02-16 | 杨喜鸿 | 促肝细胞生长素口含片 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3680114B2 (ja) | 1993-09-17 | 2005-08-10 | 敏一 中村 | 脳神経障害治療剤 |
EP1036566B1 (en) | 1997-12-03 | 2007-09-05 | Nakamura, Toshikazu | Preparation for continuous intravenous administration |
CA2339378A1 (en) | 1998-08-05 | 2000-02-17 | Sumitomo Pharmaceuticals Co., Ltd. | Preparations containing hepatocyte growth factor for treating ischemic diseases by intramuscular administration |
US6896609B2 (en) * | 2003-07-22 | 2005-05-24 | International Truck Intellectual Property Company, Llc | Driver/entry ventilation system for a bus |
CN1554338A (zh) * | 2003-12-23 | 2004-12-15 | 南京易川药物研究所 | 亚硫酸氢钠穿心莲内酯冻干制剂及其制备方法 |
EP1719521A1 (en) * | 2004-01-30 | 2006-11-08 | Mitsubishi Pharma Corporation | Preventive and/or remedy for retinopathy |
BRPI0512482A (pt) * | 2004-07-26 | 2008-03-11 | Genentech Inc | método de identificação de uma substáncia inibidora candidata e molécula antagonista |
JP2009515520A (ja) * | 2005-11-10 | 2009-04-16 | レセプター バイオロジックス, インコーポレイテッド | 肝細胞成長因子イントロン融合蛋白 |
-
2007
- 2007-02-22 WO PCT/JP2007/053316 patent/WO2008102452A1/ja active Application Filing
-
2008
- 2008-02-21 CN CNA2008800016430A patent/CN101578106A/zh active Pending
- 2008-02-21 CN CN2013102442581A patent/CN103356995A/zh active Pending
- 2008-02-21 CA CA2675622A patent/CA2675622C/en active Active
- 2008-02-21 KR KR1020097016540A patent/KR101492511B1/ko active IP Right Grant
- 2008-02-21 WO PCT/JP2008/052979 patent/WO2008102849A1/ja active Application Filing
- 2008-02-21 EP EP08711762.8A patent/EP2119449B1/en active Active
-
2009
- 2009-04-29 US US12/432,651 patent/US8461112B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6289628A (ja) * | 1985-09-11 | 1987-04-24 | Green Cross Corp:The | 人フイブリノゲン製剤の加熱処理法 |
JPH0925241A (ja) * | 1995-07-11 | 1997-01-28 | Snow Brand Milk Prod Co Ltd | Hgf凍結乾燥製剤 |
CN1579544A (zh) * | 2003-08-09 | 2005-02-16 | 杨喜鸿 | 促肝细胞生长素口含片 |
Non-Patent Citations (1)
Title |
---|
ARAKAWA R.: "Toketsu Sosa ni Oite Tenkabutsu ha Donoyoni shite Tanpakushitsu o Anteika suru noka", PROTEIN, NUCLEIC ACID AND ENZYME, vol. 37, no. 9, 1992, pages 1517 - 1523, XP003024526 * |
Also Published As
Publication number | Publication date |
---|---|
CN103356995A (zh) | 2013-10-23 |
CA2675622C (en) | 2015-10-06 |
KR20090118030A (ko) | 2009-11-17 |
EP2119449A1 (en) | 2009-11-18 |
KR101492511B1 (ko) | 2015-02-12 |
EP2119449B1 (en) | 2014-09-03 |
US8461112B2 (en) | 2013-06-11 |
US20090233863A1 (en) | 2009-09-17 |
WO2008102849A1 (ja) | 2008-08-28 |
CA2675622A1 (en) | 2008-08-28 |
EP2119449A4 (en) | 2013-05-08 |
CN101578106A (zh) | 2009-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008102452A1 (ja) | Hgf製剤 | |
IL260158B (en) | Pyrazine derivatives, preparations containing them and their uses | |
WO2009100102A3 (en) | Ts23 alpha-amylase variants with altered properties | |
WO2007124090A3 (en) | Lyophilized therapeutic peptibody formulations | |
IL204621A0 (en) | Bicyclic - ?? - amino acid derivatives, compositions comprising the same and uses thereof | |
WO2006050477A3 (en) | Anti-microbial compositions and methods of making and using the same | |
WO2009039951A3 (de) | Wirkstoffkombinationen mit insektiziden und akariziden eigenschaften | |
WO2010065969A8 (en) | Sparc binding scfcs | |
WO2008054676A3 (en) | Medical devices and methods of using the same | |
WO2007076027A3 (en) | Novel formulations of bifenthrin and enriched cypermethrin | |
WO2007086001A3 (en) | Novel pyridine derivatives | |
IL201009A0 (en) | Pyrazolo pyridine derivatives, compositions comprising the same and uses thereof | |
WO2007008384A3 (en) | Food articles with delivery devices and methods for the preparation thereof | |
WO2006096518A3 (en) | Improved gacyclidine formulations | |
EP2136638A4 (en) | MODIFIED RELEASE FORMULATIONS OF (6R) -4,5,6,7-TETRAHYDRO-N6-PROPYL-2,6-BENZOTHIAZOLE DIAMINE AND METHODS OF USE THEREOF | |
EP1831240B8 (de) | 18-methyl-19-nor-17-pregn-4-en-21,17-carbolactone, sowie diese enthaltende pharmazeutische präparate | |
IL200407A0 (en) | Stable digestive enzyme compositions, methods of producing the same and uses thereof | |
IL211892A0 (en) | Pyrazolo pyridine derivatives, compositions comprising the same and uses thereof | |
EP2165694B8 (en) | Vesicle useful for external preparation for skin, and external preparation for skin comprising the vesicle | |
WO2008036495A3 (en) | Medical balloons with modified surfaces | |
WO2010148374A3 (en) | Organo-metallic frameworks and methods of making same | |
IL211890A0 (en) | Pyrazolo pyridine derivatives, compositions comprising the same and uses thereof | |
BRPI0922435A2 (pt) | "composto de tiazolopiridina moduladores de sirtuina, composição farmacêutica compreendendo o mesmo e seu uso." | |
IL195528A (en) | Pyridazine compound, methods of preparation, a pharmaceutical composition containing it, its use and intermediate material | |
WO2006050341A3 (en) | Modified streptococcal polysaccharides and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07714813 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07714813 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |